Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Coherus and KBI Sign Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Coherus and KBI Sign Manufacturing Pact

Relates to commercial supply of CHS-1701

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Coherus BioSciences has formed a manufacturing agreement with KBI Biopharma for long-term commercial manufacturing of CHS-1701, its pegfilgrastim (Neulasta) biosimilar candidate.

KBI will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial product sales.  Coherus has recently indicated that it expects to file its CHS-1701 Biologics License Application (BLA) in the second quarter of 2016.

“We believe this agreement positions Coherus to supply CHS-1701 to patients globally for commercial launch and to continue to meet forecasted global demand for CHS-1701 for several years thereafter,” said Denny Lanfear, president and chief executive officer, Coherus. “Through this agreement, KBI Biopharma, a premier biologics manufacturer, has now allocated ample capacity for Coherus to address the substantial market potential of CHS-1701. We anticipate putting in place additional strategic manufacturing arrangements like this one for our other pipeline molecules.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics